Actual treatment of cognitive symptoms of Alzheimer's disease and future perspectives;Sadašnje liječenje kognitivnih simptoma Alzheimerove bolesti I buduće mogućnosti

Neurologia Croatica

Volumn 51, Issue 3-4, 2002, Pages 199-211+241

  Kogoj, Aleš ^a  

^a UNIVERSITY PSYCHIATRIC HOSPITAL   (Slovenia)

Author keywords

Alzheimer disease; Cholinesterase inhibitors; Drug therapy

Indexed keywords

1 (BENZO[B]THIEN 5 YL) 2 (2 DIETHYLAMINOETHOXY)ETHANOL; 1 [1 (2 TRIFLUOROMETHYL 4 PYRIMIDINYL) 4 PIPERIDINYLMETHYL] 2 PYRROLIDINONE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; AF 150 S; AF 267 B; ALPHA TOCOPHEROL; ANIRACETAM; ANTIINFLAMMATORY AGENT; CEVIMELINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CODEINE; COMPACTIN; DONEPEZIL; ESTROGEN; GALANTAMINE; GINKGO BILOBA EXTRACT; ISPRONICLINE; JPT 4819; LEVACECARNINE; LY 374973; LY 411575; MEMANTINE; METRIFONATE; MUSCARINIC AGENT; NICOTINIC AGENT; NIMODIPINE; NOOTROPIC AGENT; OXIRACETAM; PHYSOSTIGMINE; PIRACETAM; PRAMIRACETAM; PROPANIRACETAM; PROSTAGLANDIN SYNTHASE INHIBITOR; RIVASTIGMINE; ROFECOXIB; SELEGILINE; TACRINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINPOCETINE;

ABDOMINAL PAIN; AGITATION; ALZHEIMER DISEASE; ANOREXIA; CLINICAL TRIAL; COGNITIVE DEFECT; DIARRHEA; DRUG APPROVAL; DRUG MEGADOSE; FATIGUE; GENE THERAPY; HEADACHE; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; MICROGLIA; MUSCLE CRAMP; MUSCLE WEAKNESS; NAUSEA; NONHUMAN; PROTEIN INTERACTION; REVIEW; SYMPTOMATOLOGY; VERTIGO; VOMITING;

EID: 0037541052     PISSN: 03538842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. American Psychiatric Association. Practice guidelines for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry 1997; 154 (Suppl 5): 1-39.
2. Becker R, Unni L. Metrifonate: requiem or renaissance? Are selective effects of ACHE inhibitors available in AD. In: 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy; 2002 Apr 3-6; Geneva, Switzerland, 2002, p. 31.
3. Bencherif M. Neuronal nicotinic receptors: therapeutic targets for AD. In: 7th international Geneva/Springfield symposium on advances in Alzheimer therapy; 2002 Apr 3-6; Geneva, Switzerland, 2002, p. 32.
4. Birks J, Flicker L. Selegiline for Alzheimer's disease (Cochrane Review). Cochrane Database Syst Rev. 2000;(2):CD000442.
5. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease (Cochrane Review). Cochrane Database Syst Rev. 2000;(4):CD001191.
6. Birks JS, Melzer D, Beppu H. Donepezil for mild and moderate Alzheimer's disease (Cochrane Review). Cochrane Database Syst Rev 2000;(4):CD001190.
7. Brooks JO, Yesavage JA, Carta A, Bravi D. Acetyl-L-carnitine slows decline in younger patients with Alzheimer's disease. Int Psychogeriatr 1998; 10 (2): 193-203.
8. Bryson HM, Benfield P. Donepezil. Drugs Aging 1997; 10 (3): 234-9.
9. Coelho Filho JM, Birks J. Physostigmine for Alzheimer's disease (Cochrane Review). Cochrane Database Syst Rev 2001;2:CD001499.
10. Cotman C, Monaghan D, Ganong A. Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity. Annu Rev Neurosci 1988; 11: 61-80.
11. Doody RS, Stevens JC, Beck C et al. Practice parameter: management of dementia (an evidence-based review). Neurology 2001; 56: 1154-66.
12. Dysken MW, Mendels J, LeWitt P et al. Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type. J Am Geriatr Soc 1992; 40: 503-6.
13. Eriksdotter JM, Nordberg A, Amberla K et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn 1998; 9 (5): 246-57.
14. Fisher A, Pittel Z, Beach TG et al. Therapeutic opportunities for M1 muscarinic agonists. In: 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy; 2002 Apr 3-6; Geneva, Switzerland, 2002, p. 60.
15. Fleischacker W, Buchgeher A, Schubert H. Memantine in the treatment of senile dementia of the Alzheimer type. Prog Neuropsychopharmacol Biol Psychiatry 1986; 10: 87-93.
16. Flicker J, Grimley Evans G. Piracetam for dementia or cognitive impairment (Cochrane Review). Cochrane Database Syst Rev. 2001;2:CD001011.
17. Förstl H. AN-1792: A frank revolution? Int Psychogeriatr 2001; 13 (1): 3-4.
18. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;. 66: 137-47.
19. Henderson V, Paganini-Hill A, Miller V et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000; 54: 295-301.
20. Jones RW. Drug treatment in dementia. Oxford: Blackwell Science Ltd, 2000, 37-116.
21. Lopez-Arrieta JM, Rodriguez JL, Sanz F. Efficacy and safety of nicotine on Alzheimer's disease patients (Cochrane Review). Cochrane Database Syst Rev. 2001;2:CD001749.
22. Lopez-Arrieta, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia (Cochrane Review). Cochrane Database Syst Rev 2001; 1:CD000147.
23. Maelicke A, Albuquerque EX. Allosteric modulation of nicotine acetyl choline receptors as treatment strategy for Alzheimer's disease. Eur J Pharmacol 2000; 393(1-3): 165-70.
24. Maelicke A, Albuquerque EX. New approach to drug therapy in Alzheimer's disease. Drug Discov Today 1996; 1 (2): 53-9.
25. Masters CL, Beyreuther K. Alzheimer disease: the next wave of Aβ amyloid therapeutic targets. In: 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy; 2002 Apr 3-6; Geneva, Switzerland, 2002, p. 86.
26. Morich FJ, Bieber F, Lewis MJ et al. Nimodipin in the treatment of probable Alzheimer's disease. Clin Drug Invest 1996; 11(4): 185-95.
27. Mulnard R, Cotman C, Kawas C et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: a randomized, controlled trial. JAMA 2000; 283: 1007-15.
28. Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998; 55 (11): 1409-15.
29. Olin J, Schneider L, Novit A, Luczak S. Hydergine for dementia (Cochrane Review). Cochrane Database Syst Rev 2001;2:CD000359.
30. Olin J, Schneider L. Galantamine for Alzheimer's disease (Cochrane Review). Cochrane Database Syst Rev 2001;4:CD001747.
31. Ott A, Breteler MMB, van Harskamp F, Hofman A. Smoking increases the risk of dementia: the Rotterdam study. Neurology 1997; 48: A78.
32. Parkinson FE, Rudolphi KA, Fredholm BB. Propentofylline: a nucleoside transport inhibitor with neuroprotective effects in cerebral ischemia. Gen Pharmacol 1994; 25 (6): 1053-8.
33. Pharmaceutical Research and Manufacturers of America. New medicines in development for neurologic disorders. Washington: Pharma, 2001, 2-3.
34. Pharmaceutical Research and Manufacturers of America. New medicines in development for mental illnesses. Washington: Pharma, 2000, 3-4.
35. Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997; 336: 1216-22.
36. Schneider L, Tariot P. Treatment of dementia. In: Salzman C. Clinical geriatric psychopharmacology. Baltimore: Williams & Wilkins, 1998, 510-42.
37. Scott HD, Laake K. Statins for the prevention of Alzheimer's disease (Cochrane Review). Cochrane Databases Syst Rev 2001; 4: CD003160.
38. Shiovitz T, Monici P, Pietra C et al. A double-blind, placebo-controlled evaluation of the safety and tolerability of increasing doses of CHF 2819.01 (Ganstigmine) in patients with probable Alzheimer's disease. In: 7th International Geneva/Springfield Symposium on advances in Alzheimer Therapy; 2002 Apr 3-6; Geneva, Switzerland, 2002, 144.
39. Soto C, Adessi C, Saborio GP et al. β-Sheet breaker peptides for the treatment of amyloid in Alzheimer disease. In: 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy; 2002 Apr 3-6; Geneva, Switzerland, 2002, 118.
40. Tabet N, Birks J, Grimley Evans J. Vitamin E for Alzheimer's disease (Cochrane review). Cochrane Databases Syst Rev 2000; (4): CD002854.
41. Takeda M, Shinosaki K. Alzheimer pathogenesis and the future treatment strategies. IPA Bulletin 2000; 17 (4): 17-8.
42. Tollefson GD. Short term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of the primary degenerative dementia. Biol Psychiatry 1990; 27: 1133-42.
43. Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drug Aging 1994; 4 (6): 510-40.
44. Weinstock M. Selectivity of cholinesterase inhibition. Clinical implications for the treatment of Alzheimer's disease. CNS Drugs 1999; 12 (4): 307-23.
45. Winblad B, Poritis N. Memantine in severe dementia: results of the MBEST study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14: 135-46.
46. Woodwart M. Advances in Alzheimer's therapy: Sixth international Stockholm/Springfield Symposium, April 2000. IPA Bulletin 2000; 17 (3): 6-10.